Financial Performance - Sales increased by 38% year-over-year to $251.4 million in Q3 2025[11, 12] - Operating income increased significantly by 204% year-over-year to $154.6 million[16] - Net cash from operating activities before working capital was $113.9 million, or $0.37 per share[3, 16] - Free cash flow from ongoing operations reached $73.4 million, up from $57.4 million in Q2 2025[3, 16] Production and Operations - Q3 production from continuing operations was 72,462 GEO (Gold Equivalent Ounces)[3, 5] - Séguéla Mine produced 38,799 ounces of gold with cash costs of $688/oz Au and AISC of $1,738/oz Au[5] - Lindero Mine produced 24,417 ounces of gold with cash costs of $1,117/oz Au and AISC of $1,570/oz Au[5] - Caylloma Mine produced 233,612 ounces of silver with cash costs of $17.92/oz Ag Eq and AISC of $25.17/oz Ag Eq[6] Diamba Sud Gold Project - The PEA (Preliminary Economic Assessment) for Diamba Sud projects an initial 3-year average production of 147,000 ounces of gold[6] - The Diamba Sud PEA estimates construction capital costs of $283.2 million[6] - The Diamba Sud PEA indicates an after-tax NPV5% of $563 million and an after-tax IRR of 72% at a gold price of $2,750/oz[6, 7]

Financial Performance - ConocoPhillips reported adjusted earnings of $2.1 billion, resulting in an adjusted EPS of $1.78 [4] - The company generated $4.7 billion in cash from operations (CFO) and $1.8 billion in free cash flow (FCF), ending with a cash balance of $7.1 billion [4] - Share repurchases amounted to $1.2 billion, and $0.9 billion was returned to shareholders through ordinary dividends and VROC [4] - The average realized price was $54.18 per barrel of oil equivalent (BOE) [9] - Total adjusted earnings decreased from $2.601 billion in 3Q23 to $2.081 billion in 3Q24 [8] Operational Highlights - Total company production reached 1,917 MBOED (thousand barrels of oil equivalent per day) [5] - Record Lower 48 production was achieved at 1,147 MBOED [5] Strategic Decisions - The ordinary dividend was raised by 34%, and share repurchase authorization increased by up to $20 billion [4] - An agreement was signed to purchase additional working interests in Alaska [4] - Progress was made on the Marathon Oil acquisition, with an expected close in 4Q [4] Guidance - Full-year production is guided at 1.94 - 1.95 MMBOED (million barrels of oil equivalent per day) [21] - Fourth-quarter production is expected to be 1.99 - 2.03 MMBOED [21] - Full-year adjusted operating costs are projected to be $9.2B - $9.3B [21]

BlackRock TCP Capital Corp. Investor presentation Q3 2025 Key investment highlights | 1 | Established platform with decades of experience lending throughout market cycles | | --- | --- | | 2 | Strategically-positioned, diverse portfolio with access to the core middle market | | 3 | Extensive network and channel-agnostic approach to deal sourcing | | 4 | Diversified, flexible funding sources | | 5 | Strong shareholder alignment | | 6 | Access to reach and resources of world's largest asset manager | Experien ...

TURKCELL GROUP Q3 2025 NOV 6, 2025 Q3 2025 BUSINESSOVERVIEW Ali Taha Koç, PhD Turkcell CEO Another quarter of robust performance… …powered by operational excellence Revenue TRY 59.5 Billion 11.2% YoY increase EBITDA TRY 26.2 Billion 10.5% YoY increase EBITDA Margin 43.9% 0.3pp YoY decrease Net Income from continuing operations TRY 5.4 Billion 31.8% YoY increase Turkcell Group: Q3 2025 Highlights Strong Results Driven by Strategic Execution Postpaid Net Add 569 K Turkcell Fiber Net Add 33 K DC & Cloud Revenu ...

Financial Performance - Total revenue grew by 21% to USD 2,662 million for the first nine months of 2025 [43] - Operating profit increased by 52% to USD 1,007 million for the first nine months of 2025 [12, 43] - Recurring revenue grew by 26% for the first nine months of 2025 [43] - Combined commercialized medicines sales increased by 54% to USD 453 million for the first nine months of 2025 [28] Product Performance - EPKINLY net sales reached USD 333 million, a 64% increase year-over-year for the first nine months of 2025 [31] - TIVDAK net sales reached USD 120 million, a 30% increase year-over-year for the first nine months of 2025 [36] Strategic Initiatives - The company is planning to acquire Merus to deliver the next decade of sustainable growth [12, 14] - The company anticipates a first launch for petosemtamab in 2027 [17] Rina-S® Data - Rina-S® 100mg/m2 led to a confirmed ORR of 50% and a DCR of 100% in patients with advanced or recurrent endometrial cancer [26]

Q3 2025 Highlights - Production averaged 48 MBoe/D [12] - EBITDAX reached $140 million [12] - Capital expenditures decreased by over 30% from Q2, totaling $86.6 million [12] - Lease operating expenses (LOE) remained consistent with the first half of 2025 at $657 per Boe [12] - Liquidity increased by over $170 million due to extended debt maturities [12] Operational Updates - A second rig was added in mid-October [12] - A second successful simul-frac completion was implemented, resulting in an estimated savings of $25 million [12, 33] Financial Position (as of September 30, 2025) - Cash and cash equivalents stood at $165 million [36] - Total debt amounted to $12 billion [36] - Net debt was $1035 billion [36, 47] - Total liquidity, including RBL availability and cash, was $265 million [37] Hedging - 4Q25 average oil hedged is 177 MBO/d [39]

Financial Performance - Net income was $29.5 million, or $0.29 per share[11] - Adjusted Distributable Earnings were $54.2 million, or $0.53 per share[11] - The economic return for the quarter was 2.2% (non-annualized)[11] - Book value per common share was $13.40 after total dividends declared of $0.39 for the quarter[11] Portfolio Composition and Performance - The adjusted long credit portfolio increased by 11% to $3.56 billion[11, 19] - The long Agency portfolio decreased by 18% to $220.7 million[11, 27] - The Longbridge portfolio increased by 37% to $750.0 million[11, 30] Leverage and Capital Structure - The recourse debt-to-equity ratio was 1.8:1[11] - The total debt-to-equity ratio was 8.6:1, including all non-recourse borrowings[11] Loan Origination - Loans Acquired During Q3 2025 totaled $1806.5 million, including Non-QM Loans ($994.4mm), Residential Transition Loans ($186.9mm), Commercial Mortgage Loans ($126.6mm) and Reverse Mortgage Loans ($498.6mm)[37]

Financial Performance - Core reported net income of $31.6 million, or $0.61 per diluted share, and adjusted EBITDA of $141.2 million in Q3 2025, which included $18.4 million of fire extinguishment and idle mine cash costs at Leer South and a $19.4 million initial recovery of insurance proceeds related to the Leer South combustion-related event[6] - The company generated net cash provided by operating activities of $87.9 million and free cash flow of $38.9 million[6] - Core increased cash and cash equivalents by $31.5 million and overall liquidity by $47.5 million[6] Capital Return Program - Core returned $24.6 million to stockholders via share repurchases and quarterly dividends in Q3 2025, increasing the year-to-date capital return total to $218.3 million[6] - Since February 20, 2025, Core has reduced shares outstanding by approximately 5.2%[19] - As of September 30, 2025, Core had $797.4 million of remaining authorization under its existing $1.0 billion share repurchase program[22] Operational Highlights - The company achieved a strong production and sales volume performance at the Pennsylvania Mining Complex[6] - Core transitioned to a more advantageous reserve area at the West Elk mine[6] - The company raised PRB volume guidance again, taking advantage of improving domestic coal generation[6] - Core signed commitments across all segments and all periods totaling nearly 26 million tons[6] - In 2024, the company's sales volume was 85 million tons and revenue was $4.6 billion[7] Market Position and Strategy - The company has a 35% interest in Dominion Terminal Associates ("DTA")[13] - The company has 27 Mtpa export capacity via ownership interests in two marine terminals[13] - The high calorific value thermal segment has a committed book of ~17 million tons and the Powder River Basin segment has a committed book of business of ~40 million tons for delivery in 2026[28]

Portfolio Repositioning - Pebblebrook has strategically shifted its portfolio towards leisure-oriented and group-focused properties, reducing exposure to urban and corporate transient markets since 2019[15] - Resort EBITDA contribution increased from 17% to 47%, while Urban EBITDA contribution decreased from 83% to 53%[19] - The company acquired 5 upper upscale and luxury resorts for $802 million and sold 15 lower-quality urban properties for $12 billion[19] - East Coast properties now contribute 56% of EBITDA, up from 38%, while San Francisco's EBITDA contribution declined by 18%, and West Coast properties now contribute 40% of EBITDA, down from 56%[19] Financial Performance and Growth Opportunities - The company estimates a Hotel EBITDA upside of approximately $71 million, with $16 million from urban markets recovery, $45 million from ROI redevelopment projects, and $10 million from LaPlaya EBITDA growth opportunity[11, 23] - The company anticipates a potential $45+ million increase in its Urban Hotel EBITDA over the next three to four years, supported by a favorable long-term outlook[35] - Approximately $278 million of ROI capital invested is estimated to generate annual stabilized EBITDA gains of $29 to $33 million[11, 44] - LaPlaya Beach Resort & Club generated $19 million of hotel EBITDA in 2024 and is forecasting $25 million for 2025[51] Valuation and Financing - Pebblebrook's recent public market valuation reflects an approximate 55% discount to its recently calculated private market valuation of $2350 per share[11, 54, 57] - The company completed a $400 million private offering of 2030 1625% Convertible Notes, using proceeds to retire an equal amount of its 2026 175% Convertible Notes at a 2% discount to par[61, 62] - Approximately 43 million common shares were repurchased at $1156/share, increasing the effective all-in equity conversion price to $2443/share[62, 64]

Financial Performance - The company reported a revenue growth of 24% year-over-year in Q3 2025[7] - Net income attributable to Viemed was $3513000 in Q3 2025, or $009 per diluted share[7,8] - Adjusted EBITDA increased 16% year-over-year for Q3 2025, with an Adjusted EBITDA margin of 224%[7] - The company completed repurchases of 1706380 common shares for $114 million at an average price of $668 per share in Q3 2025[7] - Free cash flow for the quarter ended September 30, 2025, was $12402000[19] Operational Highlights - Vent patient growth was sustained at 9% year-over-year in Q3 2025, up 2% sequentially from Q2 2025[7] - Sleep therapy patients increased by 64% year-over-year and 21% sequentially in Q3 2025; new sleep patient starts were up 96% year-over-year, and sleep resupply patient count was up 51% year-over-year and 33% sequentially[7] - As of September 30, 2025, the company had $38 million in unfunded commitments available under its existing credit facilities[17] Revenue Mix - In Q3 2025, ventilation accounted for 49% of the service mix, while sleep accounted for 21%, oxygen for 9%, staffing for 8%, maternal for 6%, and other services for 7%[12] - Rental revenue accounted for 70% of the revenue mix, while sales accounted for 30% in Q3 2025[12] 2025 Guidance - The company projects net revenue of $271 million to $273 million[22] - Adjusted EBITDA is expected to be $60 million to $62 million, approximately 22% of net revenue[22]